HealthMore in Health→
Phase 3 Trial Finds Benralizumab Cuts Flare Risk in Rare Eosinophilic Disease
Key Takeaways
- The NATRON phase 3 study enrolled 133 patients with FIP1L1::PDGFRA-negative HES.
- Benralizumab reduced the risk of first flare versus placebo with a hazard ratio of 0.35.
- Adverse-event rates were similar between treatment and placebo groups over 24 weeks.
DE
DT Editorial Team··via nature.com